223 related articles for article (PubMed ID: 34638823)
1. Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.
Greiner J; Brown E; Bullinger L; Hills RK; Morris V; Döhner H; Mills KI; Guinn BA
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638823
[TBL] [Abstract][Full Text] [Related]
2. BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Moore AS; Alonzo TA; Gerbing RB; Lange BJ; Heerema NA; Franklin J; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2014 Apr; 61(4):647-52. PubMed ID: 24127439
[TBL] [Abstract][Full Text] [Related]
3. BIRC5 Gene Disruption via CRISPR/Cas9n Platform Suppress Acute Myelocytic Leukemia Progression.
Narimani M; Sharifi M; Hakhamaneshi MS; Roshani D; Kazemi M; Hejazi SH; Jalili A
Iran Biomed J; 2019 Nov; 23(6):369-78. PubMed ID: 31104397
[TBL] [Abstract][Full Text] [Related]
4. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
5. Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Shin HJ; Min WS; Min YH; Cheong JW; Lee JH; Kim IH; Hong DS; Ahn JS; Kim HJ; Lee WS; Jung CW; Jang JH; Park Y; Kim HJ;
Ann Hematol; 2019 May; 98(5):1135-1147. PubMed ID: 30758645
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome Profiling of Pediatric Core Binding Factor AML.
Hsu CH; Nguyen C; Yan C; Ries RE; Chen QR; Hu Y; Ostronoff F; Stirewalt DL; Komatsoulis G; Levy S; Meerzaman D; Meshinchi S
PLoS One; 2015; 10(9):e0138782. PubMed ID: 26397705
[TBL] [Abstract][Full Text] [Related]
7. Positive expression of
Yan T; Naren D; Gong Y
Expert Rev Hematol; 2020 Mar; 13(3):289-297. PubMed ID: 31990602
[No Abstract] [Full Text] [Related]
8. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
[TBL] [Abstract][Full Text] [Related]
9. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
Metzeler KH; Hummel M; Bloomfield CD; Spiekermann K; Braess J; Sauerland MC; Heinecke A; Radmacher M; Marcucci G; Whitman SP; Maharry K; Paschka P; Larson RA; Berdel WE; Büchner T; Wörmann B; Mansmann U; Hiddemann W; Bohlander SK; Buske C; ;
Blood; 2008 Nov; 112(10):4193-201. PubMed ID: 18716133
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
11. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
Estécio MR; Maddipoti S; Bueso-Ramos C; DiNardo CD; Yang H; Wei Y; Kondo K; Fang Z; Stevenson W; Chang KS; Pierce SA; Bohannan Z; Borthakur G; Kantarjian H; Garcia-Manero G
Br J Haematol; 2015 May; 169(3):344-51. PubMed ID: 25612675
[TBL] [Abstract][Full Text] [Related]
13. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
14. Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
Choi EJ; Lee JH; Kim H; Choi Y; Lee WS; Lee SM; Park JH; Park HS; Lee JH; Lee KH;
Int J Hematol; 2021 Jun; 113(6):851-860. PubMed ID: 33655416
[TBL] [Abstract][Full Text] [Related]
15. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
Carter BZ; Qiu Y; Huang X; Diao L; Zhang N; Coombes KR; Mak DH; Konopleva M; Cortes J; Kantarjian HM; Mills GB; Andreeff M; Kornblau SM
Blood; 2012 Jul; 120(1):173-80. PubMed ID: 22645176
[TBL] [Abstract][Full Text] [Related]
16. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
Zhao Y; Zhang T; Zhao Y; Zhou J
Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
[TBL] [Abstract][Full Text] [Related]
17. ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.
Yang X; Shi J; Zhang X; Zhang G; Zhang J; Yang S; Wang J; Ke X; Fu L
Biosci Rep; 2019 May; 39(5):. PubMed ID: 31028135
[TBL] [Abstract][Full Text] [Related]
18. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
19. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16).
Qiu KY; Liao XY; Li Y; Huang K; Xu HG; Fang JP; Zhou DH
BMC Cancer; 2023 May; 23(1):476. PubMed ID: 37231380
[TBL] [Abstract][Full Text] [Related]
20. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
